How effective is Gilteritinib?

Gilteritinib (Gilteritinib) is a targeted therapy drug mainly used to treat acute myeloid leukemia (Acute Myeloid FLT3 gene mutation subtypes in patients with Leukemia, AML). FLT3gene mutations are relatively common in AML, accounting for about 30% of cases. Therefore, the research and clinical trial results of gilitinib have attracted widespread attention. This article will take an in-depth look at the efficacy of giritinib, combined with clinical trial data, to gain a more comprehensive understanding of its performance in the treatment of AML.

Pharmacological effects of giritinib: As a targeted therapy, giritinib mainly works by inhibiting the activity of FLT3 receptor tyrosine kinase. FLT3Gene mutations lead to abnormal activation of FLT3 receptor tyrosine kinase, stimulating the growth and differentiation of AML cells. The high selectivity of giritinib enables it to target this abnormally activated pathway, thereby inhibiting the growth and proliferation of AML cells.

Clinical trial results:

Clinical trials of giritinib cover patients with different subtypes of AML, including newly diagnosed AML patients and relapsed/refractory AML patients. Here are some important clinical trial results:

1. RATIFYTrial: The RATIFY trial is a pivotal clinical trial designed to evaluate the efficacy of geritinib in patients with newly diagnosed FLT3-ITDmutantAML. FLT3-ITDtypeAML is usually associated with a poor prognosis. The trial results showed that patients in the geritinib treatment group had better progression-free survival (Progression-Free Survival,PFS) was significantly better than the standard chemotherapy group. Median PFS was longer in the geritinib group, suggesting it can prolong disease control. In addition, overall survival improved in the giritinib group.

2. ADMIRALTrial: The ADMIRAL trial is a study of patients with relapsed/refractoryFLT3-TKDmutantAML. FLT3-TKDtypeAMLis often insensitive to traditional treatment options. The trial results show that treatment with giritinib can lead to clinical remission in some patients, providing a new treatment option for this patient group.

3. Relapsed/RefractoryAML Treatment: Giritinib is also used for the treatment of relapsed/RefractoryAML. Conventional therapies often have limited efficacy in these patients, but clinical trials of giritinib have shown its potential to improve survival prospects in these patients. This opens up new treatment opportunities for patients whose disease relapses or is difficult to treat.

4. Improved prognosis: The use of giritinib has significantly improved the prognosis of some AML patients. Especially for those patients who carry FLT3 gene mutations, the introduction of gilitinib increases their treatment options in newly diagnosed and relapsed/refractory AML scenarios.

Giritinib, as a targeted therapeutic drug targeting FLT3 gene mutations, provides new treatment opportunities for AML patients. It has been used in the first-line treatment of AML and in relapsed /refractory AMLSignificant clinical trial results have been achieved in the treatment, improving patient prognosis. Although there are still some side effects that need to be managed, gilitinib offers hope to those with AML who have mutations in the FLT3 gene, paving the way to improve their survival prospects.

Giritinib is currently on the market in China, but it is not included in medical insurance. If patients need it, they can go to the hospital to buy it at their own expense, but the price is very high, about about 35,000 yuan. For specific prices, please consult the local hospital pharmacy. Foreign original drugs of gilitinib are even more expensive. For example, the price of the Hong Kong version of the original drug is around 90,000 yuan, and the European version of the original drug is as high as more than 200,000 yuan, which is simply unaffordable for ordinary patients. There are already foreign generic drugs of Giritinib on the market, mainly Laos generic drugs. The price is about four to five thousand yuan, which is relatively cheap. In terms of drug ingredients, the ingredients of domestic and foreign original gilitinib drugs are basically the same as those of generic drugs.